Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval expands Dupixent's indication for CSU in the EU to children as young as 2 years old

Apr. 13, 2026 at 8:24am

Got story updates? Submit your updates here. ›

An extreme close-up of a shattered car sensor lens reflecting a faint red light, conceptually illustrating the vandalism of self-driving cars.As tensions over autonomous vehicles escalate, a recent wave of targeted street vandalism exposes pent-up frustration with driverless technology.Tarrytown Today

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission (EC) has approved Dupixent® (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years with inadequate response to histamine-1 antihistamines (H1AH) and who are naïve to anti-immunoglobulin E (IgE) therapy for CSU. This expands the previous approval in the EU for adults and adolescents aged 12 years and older with CSU.

Why it matters

Young children suffering from chronic spontaneous urticaria often experience an unpredictable barrage of unrelenting itch and visible hives during the critical years of their growth and development. As the first and only targeted medicine for young children in the EU with CSU, Dupixent has the potential to become the new standard of care for those who remain symptomatic despite other available treatments.

The details

The approval in the EU is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data in adults from two Phase 3 trials (Study A and Study C) complemented by pharmacokinetic, safety and efficacy data from the single-arm CUPIDKids Phase 3 trial in children aged 2 to 11 years with CSU. The trials demonstrated that Dupixent significantly reduced urticaria activity and individual measures of itch and hive severity compared with placebo.

  • On July 4, Quinn allegedly dove onto the hood of a Waymo vehicle and covered sensors.
  • On July 29, Quinn allegedly damaged a Waymo's tires and driver's side mirror.
  • On August 11, Quinn allegedly stomped on a windshield while someone was inside.

The players

Waymo

An American autonomous driving company and is a subsidiary of Alphabet Inc., Google's parent company.

Walker Reed Quinn

A 45-year-old San Francisco resident who has a history of vandalism and was out on bail for prior cases related to Waymo vehicles.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.